Clinical trial of an inhibitor of RAGE-Ab interactions in Alzheimer disease

Neurology

Volumn 82, Issue 17, 2014, Pages 1536-1542

  Galasko, Douglas ^a   Bell, Joanne ^b   Mancuso, Jessica Y ^b   Kupiec, James W ^b   Sabbagh, Marwan N ^c,d   Van Dyck, Christopher ^e   Thomas, Ronald G ^a   Aisen, Paul S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; MEMANTINE; PF 4494700; PLACEBO;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BEHAVIOR; BRAIN FUNCTION; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; UNITED STATES;

EID: 84902173668     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000364     Document Type: Article

References (24)

1. Yan SD, Bierhaus A, Nawroth P.P., Stern DM RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis 2009; 16: 833-843.
2. Schmidt AM, Sahagan B, Nelson R.B., et al The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs 2009; 10: 672-680.
3. Fang F, Lue LF, Yan S, et al RAGE-dependent signaling in microglia contributes to neuroinflammation, A-beta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J 2010; 24:1043-1055.
4. Deane R, Du Yan S, Submamaryan RK, et al RAGE mediates amyloid beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9:907-913. (Pubitemid 36889934)
5. Deleted in proof.
6. Sabbagh MN, Agro A, Bell J., et al PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011; 25:206-212.
7. McKhann G, Drachman D, Folstein M., et al Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944. (Pubitemid 14076461)
8. Folstein MF, Folstein SE, McHugh PH "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
9. Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer's Disease. Am J Psychiatry 1984; 141:1356-1364.
10. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414. (Pubitemid 23346995)
11. Galasko D, Kershaw PR, Schneider L, et al Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc 2004; 52: 1070-1076. (Pubitemid 38869064)
12. Cummings LM, Mega M, Gray K., et al The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2304-2314.
13. Gilmore GC, Royer FL, Gruhn JJ Age differences in symbol-digit substitution task performance. J Clin Psychol 1983; 39: 114-124. (Pubitemid 13122118)
14. Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. New York: Psychological Corporation; 1981.
15. COWAT metanorms across age, education and gender. Appl Neuropsychol 2001; 8:161-166.
16. Golden GC. Stroop Color and Word Test: A Manual for Clinical and Experimental Uses. Wood Dale, IL: Stoelting; 1978.
17. Reitan R. Validity of the trail making test as an indicator of organic brain disease. Percept Mot Skills 1958; 8:271-276.
18. Sano M, Zhu CW, Whitehouse P.J., et al; The Alzheimer's Disease Cooperative Study Group. ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly. Alzheimer Dis Assoc Dis-ord 2006; 20:S191-S202. (Pubitemid 44900702)
19. Smith SC, Lamping DL, Banerjee S, et al Development of a new measure of health-related quality of life for people with dementia: DEMQOL. Psychol Med 2007; 37:737-746. (Pubitemid 46511098)
20. Fischl B, Sereno MI, Tootell R.B., Dale AM High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp 1999; 8:272-284.
21. Fischl B, Salat DH, Busa E, et al Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33:341-355. (Pubitemid 34162530)
22. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004; 14: 11-22. (Pubitemid 38018050)
23. Sperling RA, Jack CR, Black S.E., et al Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trails: recommendations form the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7:367-385.
24. Deane R, Singhe I, Sagare A.P., et al A multimodal RAGE-specific inhibitor reduces amyloid [beta]-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012; 122:1377-1392.